Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy

MT Newswires Live10-17

Verastem Oncology (VSTM) said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer demonstrated "robust" overall response rates.

The company said all evaluable patients with measurable disease showed a confirmed overall response rate of 31%, with about 12 months of follow-up and a data cutoff of June 30. The median progression-free survival was 12.9 months in all evaluable patients, Verastem added.

The company said it is on track to submit the therapy's new drug application for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer to the US Food and Drug Administration in October.

Price: 3.3796, Change: +0.05, Percent Change: +1.49

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476137621?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476137621","market":"hk","top_or_hot":-1,"title":"Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology (VSTM) said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer demonstrated \"robust\" overall response rates.</p><p>The company said all evaluable patients with measurable disease showed a confirmed overall response rate of 31%, with about 12 months of follow-up and a data cutoff of June 30. The median progression-free survival was 12.9 months in all evaluable patients, Verastem added.</p><p>The company said it is on track to submit the therapy's new drug application for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer to the US Food and Drug Administration in October.</p><p>Price: 3.3796, Change: +0.05, Percent Change: +1.49</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 17:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Verastem Oncology (VSTM) said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476137621","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476137621","pubTimestamp":1729156700,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verastem Oncology  said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer demonstrated \"robust\" overall response rates.The company said all evaluable patients with measurable disease showed a confirmed overall response rate of 31%, with about 12 months of follow-up and a data cutoff of June 30. The median progression-free survival was 12.9 months in all evaluable patients, Verastem added.The company said it is on track to submit the therapy's new drug application for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer to the US Food and Drug Administration in October.Price: 3.3796, Change: +0.05, Percent Change: +1.49","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"Verastem报告卵巢癌联合疗法2期研究更新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1},"content_text":"Verastem Oncology (VSTM) said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer demonstrated \"robust\" overall response rates.The company said all evaluable patients with measurable disease showed a confirmed overall response rate of 31%, with about 12 months of follow-up and a data cutoff of June 30. The median progression-free survival was 12.9 months in all evaluable patients, Verastem added.The company said it is on track to submit the therapy's new drug application for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer to the US Food and Drug Administration in October.Price: 3.3796, Change: +0.05, Percent Change: +1.49","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476137621"}